|
|
|
Volumn 23, Issue 14, 2003, Pages
|
|
Antibody firms move new products forward
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ADALIMUMAB;
ALEMTUZUMAB;
ANTINEOPLASTIC AGENT;
BASILIXIMAB;
DACLIZUMAB;
EDRECOLOMAB;
FC RECEPTOR;
GEMTUZUMAB OZOGAMICIN;
HUMIRA;
IBRITUMOMAB TIUXETAN;
INFLIXIMAB;
LIGAND;
MONOCLONAL ANTIBODY;
MONOCLONAL ANTIBODY 2C4;
MUROMOMAB CD3;
OKT 3;
OMALIZUMAB;
ONCOPROTEIN;
PALIVIZUMAB;
RECEPTOR PROTEIN;
RECOMBINANT ANTIBODY;
RITUXIMAB;
TRASTUZUMAB;
TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;
UNCLASSIFIED DRUG;
ANTIBODY AFFINITY;
ANTIBODY LIBRARY;
ANTIBODY SCREENING;
ANTIGEN BINDING;
APOPTOSIS;
ARTICLE;
CANCER CELL;
CELL DIFFERENTIATION;
CELL KILLING;
CELL PROLIFERATION;
CYTOTOXICITY;
DIMERIZATION;
DOWN REGULATION;
DRUG APPROVAL;
DRUG CONJUGATION;
DRUG EFFECT;
DRUG MECHANISM;
DRUG SAFETY;
GENE AMPLIFICATION;
GENETIC ENGINEERING;
HUMAN;
IMMUNOMODULATION;
INTERNALIZATION;
LIGAND BINDING;
LIVER INJURY;
LIVER TOXICITY;
MITOSIS INHIBITION;
MOLECULAR WEIGHT;
NONHUMAN;
PROTEIN EXPRESSION;
PROTEIN TARGETING;
SIGNAL TRANSDUCTION;
STAINING;
TUMOR GROWTH;
|
|
EID: 0043071501
PISSN: 02706377
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
